CSL Ltd Annual Report 2019

1 US$1,919 million in reported net profit after tax. US$1.85 total full year dividend per share. Dear Stakeholders, Each day more than 25,000 employees around the globe come to work at CSL with a shared purpose: delivering on our promise for patients. Whether they work in a laboratory, an office or one of our manufacturing sites, patients are at the centre of everything we do and our performance this year only serves to underscore our commitment. CSL once again delivered double-digit profit growth against a strong comparative period, with solid performances from our immunoglobulin, specialty products and influenza vaccines franchises. During the reporting year, we also achieved 24 product registrations or new indications for serious diseases in countries around the world. In addition to delivering solid financial results, we made significant contributions in the communities where we live and work, through both financial contributions and volunteering our time for causes our people care about. Reflecting on our performance in this report and the many ways in which our people continue to make a profound impact on improving the lives of patients and ensuring public health is a source of pride. In our industry, however, complacency is never an option. Rapid change is constantly occurring across science, medicine, technology and the markets in which we operate. These dynamics, paired with our promise to patients, compels us to persistently ask, “How can we do better?” Leading in Innovation Our ability to innovate is one way we answer this question. At CSL, innovation occurs right across the company beyond research and development (R&D). We continue to invest and expand our global R&D capabilities because we believe it is the engine that will help drive our sustainable growth. Over the reporting period, CSL invested US$832 million in R&D efforts across our businesses. This continuous improvement, however, needs to be enterprise-wide to support our sustainable growth mission. Our employees are constantly adapting the way we work to improve the efficiency of our business and the way in which we help patients. This includes in our complex global manufacturing network, rawmaterial collection and processing, developing smart technology to incorporate artificial intelligence and data analytics into the business for better outcomes and even building work environments that are flexible and encourage collaboration across all functions. Throughout CSL, we remain committed to fostering a culture in which our people feel both inspired and encouraged to come to work so patients will benefit. Our culture of innovation grounds our ability to improve our decision-making processes and ensure we are finding better, more effective, agile means of delivering our medicines to the patients we serve for years to come. CSL Limited Annual Report 2019 2 Chairman and CEO's Letter